Two Failed Antipsychotics and the Drug Held in Reserve: Starting Clozapine for Treatment-Resistant Schizophrenia in a 31-Year-Old, With the Monitoring That Makes It Safe
[Student Name]
University of Phoenix
PMH/502: Neuropsychiatric Pharmacology
Week 4 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Mr. O., a 31-year-old man with schizophrenia for nine years, continues to hear voices daily that tell him he is worthless, despite six months each of risperidone at 6 mg and olanzapine at 20 mg, with adherence confirmed by long-acting injection and pill counts. He has been hospitalized twice this year. His family asks whether anything else can help. This paper describes the decision to start clozapine.
Is This Treatment Resistance?
Treatment-resistant schizophrenia is commonly defined as persistent significant symptoms despite at least two adequate trials of different antipsychotics, each at an adequate dose for at least six weeks, with adherence confirmed. Mr. O. meets this definition. Before labeling resistance, I also check for substance use, which he denies with negative urine screens, and for medical causes, which are excluded.
The Evidence for Clozapine
Kane et al. (1988) randomly assigned patients with treatment-resistant schizophrenia to clozapine or chlorpromazine and found that about 30% improved with clozapine compared with about 4% with chlorpromazine, establishing clozapine's unique role. Siskind et al. (2016) meta-analyzed trials in treatment-refractory schizophrenia and found clozapine superior to other antipsychotics for total symptoms in both the short and long term.
Beyond Symptoms: Mortality
Tiihonen et al. (2009), in an 11-year Finnish cohort of people with schizophrenia, found that long-term antipsychotic treatment was associated with lower mortality than no treatment, and that clozapine was associated with the lowest mortality of any antipsychotic, with an adjusted hazard ratio of 0.74 compared with perphenazine. The authors suggested restrictions on clozapine use should be reassessed.
Clozapine is held in reserve because of its risks, yet in the long run it was associated with the lowest mortality of any antipsychotic in the Finnish cohort.
The Risks
Clozapine's risks are real and manageable with monitoring. Severe neutropenia is uncommon but serious, most likely in the first months. Myocarditis can occur in the first weeks. Seizures are dose-related. Constipation can progress to ileus, a potentially fatal complication. Sedation, drooling, orthostatic hypotension and weight gain with metabolic effects are common.
Baseline Assessment
Before starting, I obtain an absolute neutrophil count, complete blood count, metabolic panel, fasting glucose, lipids, weight and waist, troponin, C-reactive protein and an electrocardiogram. I review bowel habits and ask about smoking, since smoking induces CYP1A2 and lowers clozapine levels; Mr. O. smokes a pack a day.
Titration
Clozapine is started at 12.5 mg once or twice on the first day and increased slowly, typically by 25 to 50 mg a day, toward an initial target around 300 mg a day, adjusting for response, side effects and blood levels. Slow titration reduces orthostatic hypotension, sedation and seizure risk.
Monitoring
Absolute neutrophil count is checked weekly for the first six months, then every two weeks for six months, then monthly, following labeling requirements. Troponin and C-reactive protein are checked weekly for the first four weeks to detect myocarditis, with fever, chest pain or rapid heart rate prompting urgent evaluation. Bowel movements are tracked, and a stool softener and laxative are started preventively. Weight, glucose and lipids are monitored for metabolic effects. A clozapine blood level after reaching a steady dose guides adjustment, especially if he changes his smoking.
Smoking
If Mr. O. quits smoking, clozapine levels can rise sharply as CYP1A2 induction fades, risking toxicity. I explain this to him and his family and ask them to tell us before he stops or cuts down.
Why Clozapine Is Underused
Despite its evidence, clozapine is used far less than its indications would suggest. Barriers include the burden of blood monitoring, clinician unfamiliarity and concern about side effects. For Mr. O., who has been hospitalized twice this year, the burden of uncontrolled illness outweighs the burden of monitoring, and I explain this comparison to him and his family.
What Response Looks Like
Improvement with clozapine may take weeks to months, and some patients who have not improved by three months improve later at adequate levels. We agree to reassess symptoms monthly with a standardized scale, such as the Brief Psychiatric Rating Scale, and to check a clozapine level if response is limited.
Managing Common Side Effects
Drooling at night can be managed with a towel on the pillow and, if bothersome, specific medications. Sedation often improves with time and bedtime dosing. Orthostatic hypotension requires slow titration and caution when standing. Weight gain is addressed with dietary counseling and, if needed, metformin, which has evidence for reducing antipsychotic-associated weight gain.
Suicide Risk
Mr. O.'s voices tell him he is worthless, and he has had passive suicidal thoughts. Clozapine has specific evidence for reducing suicidal behavior in schizophrenia, which adds to the case for it. A safety plan is in place.
Why Not a Third Antipsychotic First
Switching to a third non-clozapine antipsychotic is sometimes tried, but after two adequate failures, the chance of response to another non-clozapine drug is low, while clozapine's advantage in treatment-resistant illness is well established (Siskind et al., 2016). Delaying clozapine prolongs illness and risk.
Registration and Logistics
Clozapine dispensing requires that monitoring results be current. I arrange blood draws at a lab near his home and coordinate with his pharmacy so that his supply is not interrupted.
Metabolic Baseline
His baseline weight is 94 kg, A1C 5.8% and triglycerides 210 mg/dL after years of olanzapine. These values set the starting point for monitoring and justify early dietary counseling.
Constipation Plan
Because clozapine slows gut movement, I start a stool softener and an osmotic laxative from the first week and ask him to report fewer than three bowel movements a week or abdominal pain, since clozapine-induced ileus can be fatal if missed.
Myocarditis Warning Signs
I teach Mr. O. and his family that fever, chest pain, shortness of breath or a racing heart in the first two months must be reported the same day, since early myocarditis is treatable when clozapine is stopped promptly.
Hope and Expectations
I tell Mr. O. that many people with treatment-resistant illness improve on clozapine, some dramatically, but that improvement takes time and requires staying with the monitoring. Setting realistic expectations supports adherence through the demanding first months.
Coordination
His long-acting risperidone injection will be stopped as clozapine is titrated, with cross-titration timed by the team to avoid a gap in treatment or a period of excess sedation.
Family Involvement
His family will help watch for fever, constipation, excessive sedation and seizures and will support blood test appointments.
Conclusion
Mr. O. meets criteria for treatment-resistant schizophrenia, and the evidence, from the original trial through a meta-analysis to a national mortality cohort, supports clozapine as the most effective option and one associated with lower mortality. Its risks, including neutropenia, myocarditis, seizures, severe constipation and metabolic effects, are addressed by a slow titration and a structured monitoring plan that makes the drug held in reserve a safe choice for him.
References
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789-796. https://doi.org/10.1001/archpsyc.1988.01800330013001
Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016). Clozapine versus first- and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis. British Journal of Psychiatry, 209(5), 385-392. https://doi.org/10.1192/bjp.bp.115.177261
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009). 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). The Lancet, 374(9690), 620-627. https://doi.org/10.1016/S0140-6736(09)60742-X
How this PMH 502 Week 4 example is structured
The PMH/502 Week 4 work usually covers antipsychotics, including metabolic and movement side effects. This paper addresses the antipsychotic with the strongest evidence and the most demanding monitoring, showing how benefit and risk are managed together. Students search this week as PMH 502 Week 4, PMH502 Wk 4 or PMH/502 Wk 4; all three are the same assignment.
PMH/502 Week 4 questions, answered
What does PMH/502 Week 4 usually ask for?
Many sections ask students to select and monitor antipsychotics, including metabolic, movement and other adverse effects.
When is clozapine used?
For treatment-resistant schizophrenia, usually defined as inadequate response to at least two different antipsychotics at adequate doses and durations, and for persistent suicidal behavior in schizophrenia.
What monitoring does clozapine require?
Absolute neutrophil count monitoring for neutropenia, plus monitoring for myocarditis early in treatment, seizures, severe constipation, sedation, orthostatic hypotension and metabolic effects.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.